EOC
MCID: OVR094
MIFTS: 38

Ovarian Epithelial Cancer (EOC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Ovarian Epithelial Cancer

MalaCards integrated aliases for Ovarian Epithelial Cancer:

Name: Ovarian Epithelial Cancer 52 29 6
Epithelial Ovarian Cancer 52 71
Ovarian Epithelial Carcinoma 52
Ovarian Cancer, Epithelial 52
Eoc 52

Classifications:



External Ids:

UMLS 71 C0677886

Summaries for Ovarian Epithelial Cancer

MalaCards based summary : Ovarian Epithelial Cancer, also known as epithelial ovarian cancer, is related to glioma and ovarian cancer. An important gene associated with Ovarian Epithelial Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and t cells.

Related Diseases for Ovarian Epithelial Cancer

Diseases related to Ovarian Epithelial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 300)
# Related Disease Score Top Affiliating Genes
1 glioma 29.3 PIK3CA CCAT2 CCAT1
2 ovarian cancer 28.2 PIK3CA ERLNC1 DNM3OS CERNA2 CCAT2 CCAT1
3 malignant epithelial tumor of ovary 11.8
4 ovarian clear cell carcinoma 11.6
5 primary peritoneal carcinoma 11.3
6 ovary transitional cell carcinoma 11.3
7 alopecia 10.5
8 fallopian tube carcinoma 10.5
9 neuropathy 10.5
10 peripheral nervous system disease 10.5
11 thrombocytopenia 10.5
12 thrombocytosis 10.5
13 clear cell adenocarcinoma 10.4
14 ovarian disease 10.4
15 mucinous adenocarcinoma 10.4
16 mucinous cystadenocarcinoma 10.4
17 appendix adenocarcinoma 10.4
18 ileus 10.4
19 infertility 10.3
20 severe combined immunodeficiency 10.3
21 47,xyy 10.3
22 insulin-like growth factor i 10.3
23 body mass index quantitative trait locus 1 10.3
24 ovarian serous carcinoma 10.3
25 sensory peripheral neuropathy 10.3
26 stomatitis 10.3
27 granulocytopenia 10.3
28 familial ovarian cancer 10.3
29 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
30 pelvic inflammatory disease 10.3
31 endometriosis of ovary 10.3
32 constipation 10.3
33 lynch syndrome 10.3
34 b-cell lymphoma 10.3
35 cytokine deficiency 10.3
36 acute sensory ataxic neuropathy 10.3
37 colorectal cancer 10.2
38 epileptic encephalopathy, childhood-onset 10.2
39 diarrhea 10.2
40 ovarian cystadenoma 10.2
41 adenoma 10.2
42 breast cancer 10.2
43 retinoblastoma 10.2
44 body mass index quantitative trait locus 11 10.2
45 deficiency anemia 10.2
46 exanthem 10.2
47 carcinosarcoma 10.2
48 familial retinoblastoma 10.2
49 hereditary breast ovarian cancer syndrome 10.2
50 48,xyyy 10.2

Graphical network of the top 20 diseases related to Ovarian Epithelial Cancer:



Diseases related to Ovarian Epithelial Cancer

Symptoms & Phenotypes for Ovarian Epithelial Cancer

Drugs & Therapeutics for Ovarian Epithelial Cancer

Drugs for Ovarian Epithelial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 409)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Olaparib Approved Phase 4 763113-22-0 23725625
4 HIV Protease Inhibitors Phase 4
5
protease inhibitors Phase 4
6 BB 1101 Phase 4
7 Autonomic Agents Phase 4
8 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
9
Melphalan Approved Phase 3 148-82-3 4053 460612
10
Sodium citrate Approved, Investigational Phase 3 68-04-2
11
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
12
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
13
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
17
Acyclovir Approved Phase 3 59277-89-3 2022
18
Ribavirin Approved Phase 3 36791-04-5 37542
19
Palivizumab Approved, Investigational Phase 3 188039-54-5
20
Captopril Approved Phase 3 62571-86-2 44093
21
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
22
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
23
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
24
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
25
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
26
Bevacizumab Approved, Investigational Phase 3 216974-75-3
27
Gemcitabine Approved Phase 3 95058-81-4 60750
28
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
29
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
30
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
31
Talazoparib Approved, Investigational Phase 3 1207456-01-6 135565082
32
Adenosine Approved, Investigational Phase 3 58-61-7 60961
33
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
34
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
35
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
36
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
37
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
38
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
39
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
40
Polyestradiol phosphate Approved Phase 3 28014-46-2
41
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
42
Mycophenolic acid Approved Phase 3 24280-93-1 446541
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
44
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
45
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
46 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
47
Trebananib Investigational Phase 3 894356-79-7
48 Gastrointestinal Agents Phase 3
49 Alkylating Agents Phase 3
50 Citrate Phase 3

Interventional clinical trials:

(show top 50) (show all 889)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
3 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
4 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
5 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
6 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Not yet recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
7 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
8 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
9 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
10 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
11 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
12 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
13 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
14 The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
15 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
16 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
17 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
18 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
19 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
20 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
21 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
22 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
23 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
24 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
25 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
26 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
27 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
28 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
29 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
30 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
31 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
32 Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial Completed NCT00004166 Phase 3 amifostine trihydrate
33 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine
34 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
35 A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
36 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
37 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
38 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
39 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
40 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
41 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
42 A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
43 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
44 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
45 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
46 A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression Completed NCT01684878 Phase 3 Gemcitabine (Chemotherapy);Paclitaxel (Chemotherapy);Pertuzumab;Placebo;Topotecan (Chemotherapy)
47 Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
48 A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
49 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
50 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel

Search NIH Clinical Center for Ovarian Epithelial Cancer

Genetic Tests for Ovarian Epithelial Cancer

Genetic tests related to Ovarian Epithelial Cancer:

# Genetic test Affiliating Genes
1 Ovarian Epithelial Cancer 29

Anatomical Context for Ovarian Epithelial Cancer

MalaCards organs/tissues related to Ovarian Epithelial Cancer:

40
Ovary, Breast, T Cells, Lymph Node, Testes, Endothelial, Bone

Publications for Ovarian Epithelial Cancer

Articles related to Ovarian Epithelial Cancer:

(show top 50) (show all 9186)
# Title Authors PMID Year
1
SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. 61
31503345 2020
2
Prediction of Epithelial Ovarian Cancer Outcomes With Integration of Genomic Data. 61
31789830 2020
3
Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer. 61
31855903 2020
4
Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. 61
31876639 2020
5
microRNA-141-3p-containing small extracellular vesicles derived from epithelial ovarian cancer cells promote endothelial cell angiogenesis through activating the JAK/STAT3 and NF-κB signaling pathways. 61
32034654 2020
6
Para-aortic lymphadenectomy below inferior mesenteric artery versus renal vessels in stage IIIC epithelial ovarian cancer: A comparison of surgical outcomes. 61
31746467 2020
7
Expression and clinical significance of WWOX, Elf5, Snail1 and EMT related factors in epithelial ovarian cancer. 61
31966058 2020
8
A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals. 61
31923082 2020
9
Gender of offspring and risk of ovarian cancer: The HOPE study. 61
31835157 2020
10
Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. 61
31561176 2020
11
Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer. 61
32008138 2020
12
Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. 61
31743133 2020
13
Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. 61
32034256 2020
14
Peritoneal and upper genital tract tuberculosis. 61
31663322 2020
15
Knockdown of enhancer of rudimentary homolog inhibits proliferation and metastasis in ovarian cancer by regulating epithelial-mesenchymal transition. 61
32036222 2020
16
Lung and Intercostal Upper Abdomen Ultrasonography for Staging Patients with Ovarian Cancer: A Method Description and Feasibility Study. 61
32033429 2020
17
CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway. 61
31541326 2020
18
Effect of progesterone and first evidence about allopregnanolone action on the progression of epithelial human ovarian cancer cell lines. 61
31614205 2020
19
Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation. 61
31614206 2020
20
Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed? 61
31421122 2020
21
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis. 61
31902551 2020
22
Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. 61
32039764 2020
23
miR-200c overexpression inhibits the invasion and tumorigenicity of epithelial ovarian cancer cells by suppressing lncRNA HOTAIR in mice. 61
31535411 2020
24
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. 61
31650446 2020
25
Hormonal management of menopausal symptoms in women with a history of gynecologic malignancy. 61
31738735 2020
26
Sohlh2 alleviates malignancy of EOC cells under hypoxia via inhibiting the HIF1α/CA9 signaling pathway. 61
31318683 2020
27
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. 61
32028974 2020
28
Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary. 61
31796530 2020
29
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. 61
32037195 2020
30
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100®. 61
31774247 2020
31
Histological Tumor Type is Associated with One-Year Cause-Specific Survival in Women with Stage III-IV Epithelial Ovarian Cancer: A Surveillance, Epidemiology, and End Results (SEER) Database Population Study, 2004-2014. 61
32008036 2020
32
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. 61
31862634 2020
33
LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity. 61
31815680 2020
34
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. 61
31952843 2020
35
A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. 61
31746425 2020
36
Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. 61
31865042 2020
37
Pre-operative serum CA125, peritoneal cancer index and intra-operative mapping score as predictors of surgical results in primary epithelial ovarian cancer. 61
31744887 2020
38
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. 61
31924332 2020
39
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. 61
31919136 2020
40
First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. 61
31041717 2020
41
Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer. 61
31949501 2020
42
Mutually exclusive antiproliferative effect of cell line-specific HOX inhibition in epithelial ovarian cancer cell lines: SKOV-3 vs RMUG-S. 61
31970886 2020
43
Targeted activation of Stat3 in combination with paclitaxel results in increased apoptosis in epithelial ovarian cancer cells and a reduced tumour burden. 61
31778258 2020
44
The expression levels and clinical significance of MFG-E8 and CD133 in epithelial ovarian cancer. 61
31899997 2020
45
ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2-/- Ovarian Cancer Cells. 61
31534014 2020
46
PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming. 61
31922217 2020
47
Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer. 61
31936170 2020
48
A TAZ-ANGPTL4-NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. 61
31641008 2020
49
Recurrence patterns in patients with abnormal cardiophrenic lymph nodes at ovarian cancer diagnosis. 61
31953350 2020
50
Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer. 61
31822507 2020

Variations for Ovarian Epithelial Cancer

ClinVar genetic disease variations for Ovarian Epithelial Cancer:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
2 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)SNV Pathogenic/Likely pathogenic 13655 rs104886003 3:178936091-178936091 3:179218303-179218303
3 PIK3CA NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys)SNV Pathogenic/Likely pathogenic 13657 rs121913286 3:178936094-178936094 3:179218306-179218306

Expression for Ovarian Epithelial Cancer

Search GEO for disease gene expression data for Ovarian Epithelial Cancer.

Pathways for Ovarian Epithelial Cancer

GO Terms for Ovarian Epithelial Cancer

Sources for Ovarian Epithelial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....